Roivant Q3 revenue falls to $9.0 million; continuing loss of $208.9 million
Roivant reported results for the quarter ended December 31, 2024. Revenue fell to $9.0 million from $15.6 million a year earlier, and the loss from continuing operations was $208.9 million, or $0.22 per share, compared with income of about $5.1 billion a year earlier, which included a one-time Telavant gain. Net income attributable to Roivant was $169.4 million, driven by a $327.0 million gain from discontinued operations tied to the sale of Dermavant to Organon.
Key points
- Revenue, net was $9.0 million for the three months ended December 31, 2024, versus $15.6 million a year earlier.
- R&D expenses rose $33.4 million to $141.6 million; G&A expenses rose $13.4 million to $141.5 million.
- Income from discontinued operations was $327.0 million, reflecting the October 2024 sale of Dermavant to Organon.
- Consolidated cash, cash equivalents, restricted cash and marketable securities were about $5.2 billion at December 31, 2024.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 10, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.